Introduction
============

There is no consensus on the definition of obesity or on specific aspects of obesity that contribute to the risk of CVD \[[@B1]\]. The precise measurement of the total amount of body fat and its regional distribution is possible by using computed tomography (CT), dual-energy X-ray absorption \[[@B2]\]. Magnetic resonance imaging (MRI), like CT, can separate visceral fat from subcutaneous fat and since there is no radiation involved, it can perform a total body scan for maximal accuracy and fat distribution. However, these methods are primarily used at the research level. Besides, they are time-consuming, costly, and not routinely available. Accordingly there is a need for simple techniques that can discriminate regional fat. Amato et al. have recently individuated a novel sex-specific index based on waist circumference, body mass index (BMI), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), and indirectly expressing visceral fat \[[@B3]\] and termed it the visceral adiposity index (VAI). VAI had significant correlation with visceral adiposity and its increase was strongly associated with cardiometabolic risk. However, the prospective relation between VAI and CVD is less clear \[[@B3]\]. Clinical importance of visceral adiposity lies in its association with health risks like CVD. Therefore, from clinical point-of-view, indices developed to measure visceral adiposity should be examined with respect to their ability to predict risks known to be associated with it \[[@B4],[@B5]\].

Using data from a large community-based study, we examined if VAI would improve CVD prediction currently made by multivariate algorithms and if VAI could add to the predictive ability of the simple anthropometric measures of adiposity i.e. BMI, waist-to-height ratio (WHtR) or waist-to-hip ratio (WHpR).

Methods
=======

Study population
----------------

Detailed descriptions of the Tehran lipid and glucose study (TLGS) have been reported elsewhere \[[@B6]\]; in brief, the TLGS is a large scale, long term, community-based prospective study performed on a representative sample of residents of district 13 of Tehran, the capital of Iran. The TLGS has two major components: a cross-sectional prevalence study of noncommunicable disease and associated risk factors, implemented between March 1999 and December 2001, and a prospective follow-up study. Data collection is ongoing, designed to continue for at least 20 years, at 3-year intervals. Participants were categorized into the cohort (n = 9375) and intervention groups (n = 5630), the latter to be educated for implementation of life style modifications. For the current study, among participants aged ≥ 30 (n = 8,071), we selected those who participated in the follow-up study until 20 March 2009 (n = 7,154). After exclusions (344 prevalent CVD and 382 missing data), 6,407 (2,778 men) participants remained eligible (response rate 95%), contributing to a 54,950 person-year follow up. At the time of this study, the median follow up time was 9.1 years. Participants were provided with information regarding the results of their examinations and were given appropriate medical advice.

Clinical and laboratory measurements
------------------------------------

Using a pretested questionnaire, a trained interviewer collected information on demographic data, family history of premature CVD, past medical history of CVD, and smoking status. Detailed description of clinical and laboratory measurements has been provided in appendices. Weight was measured, with subjects minimally clothed without shoes, using digital scales (Seca 707: range 0.1-150 kg) and recorded to the nearest 100 g. Height was measured in a standing position without shoes, using tape meter while shoulders were in a normal alignment. Waist circumference (WC) was measured at the umbilical level and that of the hip at the maximum level over light clothing, using an unstretched tape meter, without any pressure to body surface and measurements were recorded to the nearest 0.1 cm \[[@B7]\]. BMI (kg.m^-2^) was calculated as weight (kg) divided by square of the height (m^2^). WHpR was calculated as WC (cm) divided by hip circumference (cm) and WHtR was calculated as WC divided by height (cm). After a 15-minute rest in the sitting position, two measurements of blood pressure were taken, on the right arm, using a standardized mercury sphygmomanometer (calibrated by the Iranian Institute of Standards and Industrial Researches); the mean of the two measurements was considered as the participant\'s blood pressure.

A blood sample was drawn between 7:00 and 9:00 AM from all study participants, after 12 to 14 hours overnight fasting. All the blood analyses were undertaken at the TLGS research laboratory on the day of blood collection. Plasma glucose was measured using an enzymatic colorimetric method with glucose oxidase. Fasting plasma glucose (FPG) measurement was performed for all participants, and the standard 2-hour post-challenge plasma glucose (2 h-PCPG) test for those not on glucose-lowering drugs. Total cholesterol (TC) was assayed, using the enzymatic colorimetric method with cholesterol esterase and cholesterol oxidase. High-density lipoprotein cholesterol (HDL-C) was measured after precipitation of the apolipoprotein B containing lipoproteins with phosphotungistic acid. TGs were assayed using enzymatic colorimetric assay with glycerol phosphate oxidase. Analyses were performed using Pars Azmon kits (Pars Azmon Inc., Tehran, Iran) and a Selectra 2 auto-analyzer (Vital Scientific, Spankeren, Netherlands). All samples were analyzed when internal quality control met the acceptable criteria. The intra and inter-assay coefficients of variation were both \< 2.2% for plasma glucose, and 0.5 and 2% for TC, respectively \[[@B6]\].

Outcome measurements
--------------------

Details of cardiovascular outcomes have been published elsewhere \[[@B8]\]. In this ongoing study every TLGS\' participant is followed up for any medical event during the previous year, by telephone. They are questioned by a trained nurse regarding any medical conditions or whether a related event have occurred, a trained physician collects complementary data during a home visit and a visit to the respective hospital to collect data from the participants medical files. In the case of mortality, data are collected from the hospital or the death certificate by an authorized local physician. Collected data are evaluated by an outcome committee consisting of a principal investigator, an internist, an endocrinologist, a cardiologist, an epidemiologist, and the physician who collects the outcome data. Other experts are invited for evaluation of non-communicable disorders, as needed. A specific outcome for each event is assigned according to International Statistical Classification of Diseases and Related Health Problems criteria (10th Revision), and the American Heart Association classification for cardiovascular events \[[@B6],[@B9],[@B10]\]. Coronary heart disease (CHD) includes cases of definite myocardial infarction (MI) diagnosed by electrocardiogram (ECG) and biomarkers, probable MI (positive ECG findings plus cardiac symptoms or signs and biomarkers showing negative or equivocal results), unstable angina pectoris (new cardiac symptoms or changing symptom patterns and positive ECG findings with normal biomarkers), angiographic proven CHD and CHD death. CVD is specified as a composite measure of any CHD events, stroke, or cerebrovascular death.

Definition of terms
-------------------

Following Amato et al. \[[@B3]\] we defined VAI as:

$$\begin{array}{l}
{\textsf{Males} = \left( \frac{\textsf{WC}}{39.68 + 1.88 \times \textsf{BMI}} \right) \times \left( \frac{\textsf{TGs}}{1.03} \right) \times \left( \frac{1.31}{\textsf{HDL~-~C}} \right)} \\
{\textsf{Females} = \left( \frac{\textsf{WC}}{36.58 + 1.89 \times \textsf{BMI}} \right) \times \left( \frac{\textsf{TGs}}{0.81} \right) \times \left( \frac{1.52}{\textsf{HDL~-~C}} \right)} \\
 \\
\end{array}$$

assuming VAI = 1 in healthy non-obese subjects with normal adipose distribution and normal TG and HDL levels. A previous history of CVD reflected any prior diagnosis of CVD by a physician. A current smoker was defined as a person who smokes cigarettes daily or occasionally. Participants using oral hypoglycemic agents or insulin were considered as having diabetes. Diabetes was also ascertained in participants with FPG ≥ 7.0 mmol.l^-1^or 2 h-PCPG ≥ 11.1 mmol.l^-1^\[[@B11]\]. Non-HDL-C was calculated by subtracting HDL-C from total cholesterol. For each participant, free of CVD at baseline, the baseline risk of CVD was calculated by re-estimating the Framingham\'s \"general CVD risk prediction algorithm \[[@B12]\].

Statistics analysis
-------------------

Findings on covariate variables are expressed as means (SD) or percentages for continuously distributed and categorical variables, respectively. We tested for trends across VAI quintiles by using the median in each quartile as a predictor, separately for each sex. Statistical significance in trends was examined by implementing General Linear Models. The Log-Rank test and Cox test were used to examine the significance of trends in incident rates and survivor functions.

In the analysis of CVD outcome, VAI, BMI, WHpR and WHtR were assessed using accelerated failure time method: Weibull survival regression model. Survival time was the time from start of the follow-up period to the date of the first incident, CVD event (failure). The censoring time of an individual was the time from entry into the study to loss to follow-up or the end of the study, whichever happened first. Censored observation meant the individuals either refused to participate further in the study (lost to follow-up), died (from none-CVD causes), when death was not the study outcome (competing risk) or continued until the study was ended (administrative censoring). Valid comparison of hazards ratios (HRs) for different continuous measures requires that the units of both variables to be comparable. We, thus, estimated sex-specific age-adjusted hazard ratios (HRs), with 95% confidence intervals (CI) for CVD events for a one-SD increment in VAI and each respective anthropometric parameter. We controlled our regression analyses for cofounding bias due to potential confounders i.e. age, systolic blood pressure, using antihypertensive drugs, total and HDL cholesterol, diabetes and smoking \[[@B13]\].

We compared predictive performance of the VAI with those of the studied anthropometric variables in terms of the effect size (HR), calibration and discrimination, added predictive ability, and explained variation.

Wald tests of the linear hypotheses concerning the Weibull survival regression models coefficients (paired homogeneity test) were performed to test the null hypotheses that the hazard ratios (effect size) for VAI were equal to those for anthropometric measures. We assessed collinearity of BMI, WHpR, and WHtR, with VAI using variance inflation factor (VIF). VIFs \> 10 warrant caution \[[@B14]\].

Calibration, as it is phrased in reference \[[@B15]\] describes how closely predicted probabilities agree numerically with actual outcomes \[[@B16],[@B17]\]. A test very similar to the Hosmer-Lemeshow test has been proposed by Nam and D\'Agostino. We calculated the NamD\'Agostino *χ^2^*to examine calibration for prediction models \[[@B15]\]. As suggested by D\'Agostino and Nam, calibration chi-square values greater than 20 (P \< 0.01) suggest lack of adequate calibration \[[@B15]\].

Discrimination is the ability of a prediction model to separate those who develop incident CVD events from those who do not and is quantified by the Harrell\'s *C*statistic \[[@B18]\]. In the survival analysis, *C*statistic \[[@B19]\] measures the probability that a randomly selected person who developed an event, at the certain specific time has a higher risk score than a randomly selected person who did not develop an event during the same, specific follow-up interval \[[@B20]\].

Discriminations measures are not sensitive to changes in absolute risk \[[@B21]\]. We, thus, calculated absolute and relative integrated discrimination improvement index *(*IDI) and cut-point-based and cut-point-free net reclassification improvement index (NRI). IDI and NRI are measures of predictive ability added to an old model by a newer one \[[@B21]\]. Bootstrapping method was implemented in order to obtain bias-corrected 95% confidence intervals (95% CIs).

We hereby certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. Informed written consent was obtained from all participants and the Ethical Committee of Research Institute for Endocrine Sciences approved this study.

The statistical significance level was set at a two-tailed type I error of 0.05. All statistics analyses were performed using STATA version 12 (STATA, College Station, Texas USA) and SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
=======

For a median follow up of 9 years, 6,407 (3,629 women) adult participants of the TLGS contributed to a total of 54,950 person-years follow up. We documented 534 CVD events with the annual incidence rate of CVD events being 9.7 (95% 8.9-10.6) per 1000 person: women 7.3 (6.4-8.3) and men 13.0 (11.7-14.6).

Participants\' characteristics are shown according to baseline VAI quintiles in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. In general, CVD risk factors levels at baseline increased in stepwise fashion across VAI quintiles; except for smoking. The annual incidence rate of CVD events showed an increasing trend across quintiles of VAI among women (P \< 0.001). Age-adjusted survival functions for quintiles of VAI have been compared in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. Age-adjusted CVD-free survival probability decreased significantly across VAI quintiles among both men and women (P values \< 0.001).

###### 

Basal characteristics of participants across VAI quintiles, among men

                            Q1               Q2                 Q3                Q4                 Q5                 
  ------------------------- ---------------- ------------------ ----------------- ------------------ ------------------ ----------
  Age (years)               41.43 (10.86)    45.18 (11.36)      47.70 (11.80)     48.30 (11.64)      49.79 (11.11)      0.010
  Life style modification   263 (0.4)        220 (0.39)         221 (0.36)        185 (0.39)         190 (0.41)         0.764
  Smoking                   184 (0.28)       157 (0.28)         177 (0.29)        132 (0.28)         144 (0.31)         0.451
  Diabetes                  32 (0.05)        44 (0.08)          66 (0.11)         89 (0.19)          100 (0.22)         \< 0.001
  Anti-hypertensive drug    46 (0.07)        39 (0.07)          43 (0.07)         38 (0.08)          32 (0.07)          0.720
  SBP (mm Hg)               113.73 (16.81)   119.67 (18.71)     123.54 (20.84)    126.18 (21.21)     129.35 (21.43)     \< 0.001
  DBP (mm Hg)               74.98 (9.81)     78.03 (10.26)      80.16 (10.90)     81.35 (10.73)      82.83 (10.62)      \< 0.001
  Weight (kg)               64.06 (10.95)    67.41 (12.08)      69.62 (11.33)     71.27 (12.43)      72.12 (11.18)      \< 0.001
  Waist (cm)                82.01 (10.83)    87.93 (11.67)      91.12 (10.95)     93.68 (11.31)      96.31 (10.17)      \< 0.001
  Height (cm)               156.46 (5.78)    156.13 (6.11)      155.25 (5.69)     155.54 (5.92)      155.27 (5.76)      \< 0.001
  Hip circumference (cm)    102.24 (8.78)    104.40 (9.34)      106.00 (9.59)     106.77 (9.50)      106.82 (9.14)      \< 0.001
  BMI (kg.m^-2^)            26.20 (4.50)     27.66 (4.73)       28.90 (4.58)      29.42 (4.63)       29.90 (4.25)       \< 0.001
  WHpR                      80.16 (7.37)     84.20 (7.97)       86.01 (7.52)      87.77 (7.74)       90.30 (7.50)       \< 0.001
  WHtR                      52.51 (7.40)     56.42 (7.93)       58.77 (7.43)      60.29 (7.43)       62.10 (6.81)       \< 0.001
  TC (mmol.l^-1^)           5.07 (0.96)      5.39 (1.03)        5.76 (1.07)       5.97 (1.15)        6.30 (1.35)        \< 0.001
  HDL-C (mmol.l^-1^)        1.43 (0.27)      1.28 (0.25)        1.16 (0.21)       1.06 (0.19)        0.91 (0.18)        \< 0.001
  TGs (mmol.l^-1^)          0.86 (0.21)      1.28 (0.28)        1.70 (0.34)       2.19 (0.44)        3.59 (1.38)        \< 0.001
  Ln-TGs                    -0.19 (0.26)     0.23 (0.21)        0.51 (0.20)       0.76 (0.20)        1.22 (0.32)        \< 0.001
  FPG (mmol.l^-1^)          5.01 (1.17)      5.26 (1.55)        5.53 (2.00)       5.91 (2.46)        6.23 (2.59)        \< 0.001
  PCPG (mmol.l^-1^)         5.79 (1.76)      6.25 (2.16)        6.94 (3.18)       7.56 (3.35)        8.35 (3.90)        \< 0.001
  Incident CVD              9.7 (7.4-12.6)   13.9 (10.9-17.7)   12.3 (9.7-15.8)   15.3 (11.9-19.7)   15.2 (11.8-19.7)   0.076

BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; MAP, mean arterial pressure; PCPG, 2-hour post-challenge plasma glucose; SBP, systolic blood pressure; TC, total cholesterol; TGs, triglycerides; VAI, visceral adiposity index; WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio

###### 

Basal characteristics of participants across VAI quintiles, among women

                            Q1               Q2               Q3               Q4                Q5                
  ------------------------- ---------------- ---------------- ---------------- ----------------- ----------------- ----------
  Age (years)               49.11 (14.46)    48.5 (13.32)     48.27 (12.78)    48.46 (12.55)     46.97 (11.87)     \< 0.001
  Life style modification   250 (0.38)       285 (0.40)       256 (0.38)       315 (0.40)        303 (0.39)        0.874
  Smoking                   26 (0.04)        21 (0.03)        32 (0.05)        26 (0.03)         28 (0.04)         0.846
  Diabetes                  22 (0.03)        47 (0.07)        86 (0.13)        150 (0.20)        202 (0.27)        \< 0.001
  Anti-hypertensive drug    53 (0.08)        101 (0.14)       121 (0.18)       151 (0.19)        197 (0.25)        \< 0.001
  Lipid lowering drug       7 (0.01)         11 (0.02)        16 (0.02)        44 (0.06)         98 (0.13)         \< 0.001
  SBP (mm Hg)               120.28 (20.67)   121.48 (21.20)   123.49 (19.52)   123.22 (16.87)    124.92 (18.51)    \< 0.001
  DBP (mm Hg)               75.91 (11.83)    77.66 (11.57)    79.79 (11.60)    80.03 (10.27)     80.73 (11.31)     \< 0.001
  Weight (kg)               67.94 (11.85)    73.70 (11.28)    76.37 (11.45)    78.47 (11.72)     80.30 (11.53)     \< 0.001
  Waist (cm)                82.91 (10.83)    88.91 (10.01)    91.64 (9.58)     93.85 (9.29)      95.69 (8.85)      \< 0.001
  Height (cm)               168.79 (7.05)    169.09 (6.48)    169.11 (6.48)    168.74 (5.93)     169.34 (6.70)     \< 0.001
  Hip circumference (cm)    93.12 (6.73)     96.22 (6.62)     97.41 (6.06)     98.36 (6.67)      99.05 (6.50)      \< 0.001
  BMI (kg.m^-2^)            23.84 (3.85)     25.79 (3.79)     26.67 (3.45)     27.52 (3.54)      27.97 (3.39)      \< 0.001
  WHpR                      88.81 (7.17)     92.26 (6.50)     93.96 (6.28)     95.35 (6.01)      96.59 (6.20)      \< 0.001
  WHtR                      49.20 (6.67)     52.67 (6.41)     54.24 (5.77)     55.65 (5.43)      56.56 5.37 ()     \< 0.001
  TC (mmol.l^-1^)           4.94 (0.98)      5.36 (0.99)      5.50 (1.01)      5.63 (1.07)       5.87 (1.15)       \< 0.001
  HDL-C (mmol.l^-1^)        1.22 (0.26)      1.04 (0.18)      0.95 (0.17)      0.87 (0.16)       0.77 (0.15)       \< 0.001
  TGs (mmol.l^-1^)          0.98 (0.26)      1.51 (0.28)      2.01 (0.39)      2.62 (0.50)       4.35 (1.63)       \< 0.001
  Ln-TGs                    -0.06 (0.28)     0.39 (0.19)      0.68 (0.19)      0.95 (0.19)       1.41 (0.32)       \< 0.001
  FPG (mmol.l^-1^)          5.26 (1.44)      5.26 (1.17)      5.47 (1.64)      5.80 (1.98)       6.07 (2.34)       \< 0.001
  PCPG (mmol.l^-1^)         5.80 (2.79)      6.08 (2.77)      6.61 (3.18)      7.09 (4.01)       7.66 (4.01)       \< 0.001
  Incident CVD              2.4 (1.4-4.1)    3.9 (2.7-5.8)    6.3 (4.5-8.7)    10.7 (8.5-13.5)   11.9 (9.5-14.8)   \< 0.001

BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; MAP, mean arterial pressure; PCPG, 2-hour post-challenge plasma glucose; SBP, systolic blood pressure; TC, total cholesterol; TGs, triglycerides; VAI, visceral adiposity index; WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio

![**Age-adjusted survival curves across quintiles of the visceral adiposity index: men**.](1475-2840-11-20-1){#F1}

![**Age-adjusted survival curves across quintiles of the visceral adiposity index: women**.](1475-2840-11-20-2){#F2}

Risk of future CVD increased with increasing levels of VAI among both men and women. Among women, but not men, the increased risk resisted adjustments for the CVD risk factors (Table [3](#T3){ref-type="table"}). As shown in Table [3](#T3){ref-type="table"}, HRs for CVD of WHpR and WHtR were consistently higher than those of VAI among both men and women. These superiorities, however, did not reach statistical significance.

###### 

Hazard ratios for incident CVD of VAI vs. WHpR and WHtR

                                                HR 95% CIs         **vs. VAI**^**a**^
  ------------------------------ ------- ------ ------------------ --------------------
                                 Men     VAI    1.18 (1.07-1.30)   \-
                                         WHpR   1.37 (1.22-1.55)   0.061
                                         WHtR   1.38 (1.21-1.58)   0.068
                                         BMI    1.28 (1.13-1.45)   0.355
  Age-adjusted                   Women   VAI    1.27 (1.18-1.37)   \-
                                         WHpR   1.52 (1.31-1.76)   0.133
                                         WHtR   1.45 (1.27-1.66)   0.229
                                         BMI    1.26 (1.12-1.43)   0.682
                                 Men     VAI    1.05 (0.94-1.18)   \-
                                         WHpR   1.23 (1.07-1.40)   0.078
                                         WHtR   1.21 (1.05-1.39)   0.123
                                         BMI    1.08 (0.95-1.23)   0.301
  Multivariate-adjusted^b,\ c^   Women   VAI    1.17 (1.07-1.28)   \-
                                         WHpR   1.42 (1.22-1.65)   0.078
                                         WHtR   1.36 (1.18-1.56)   0.146
                                         BMI    1.04 (1.01-1.07)   0.352

CVD, cardiovascular disease; HR, hazard ratio; VAI, visceral adiposity index; WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio

a\. *P*values were derived from Wald tests of the linear hypotheses concerning the Weibull regression models coefficients (paired homogeneity test). As such, we tested the null hypotheses that the hazard ratios (effect size) for VAI were equal to those for WHpR, WHtR, or BMI

b\. Adjusted for the effects of age, systolic blood pressure, anti-hypertensive medication use, total and high-density lipoprotein cholesterol, diabetes, and smoking

c\. To avoid over-adjustment, VAI was not adjusted for high-density lipoprotein cholesterol since it was a component of VAI

We observed that among men, 0.7% (95% CIs 0.09-1.9%) of variations in CVD-free survival time was explained VAI. The corresponding figures were 4.5% (95% CIs 2.4-7.2%) for WHtR, 6.1 (95% CIs 3.6-9.0%) for WHpR, and 0.8% (95% CIs 0.1-2.2%) for BMI. Among women, 5.0% (95% CIs 2.7-7.8%) of variations in CVD-free survival time was explained VAI. The corresponding figures were 7.3% (95% CIs 4.5-10.7%) for WHtR, 10.0 (95% CIs 6.6-13.9%) for WHpR, and 1.4% (95% CIs 0.4-3.0%) for BMI.

Harrell\'s *C*(95% CIs) and Nam-D\'Agostino *χ*^2^(P for lack of fit) for the CVD risk based on the Framingham general CVD algorithm were 0.777 (0.754-0.802) and 15.8 (0.070) among men; the corresponding figures were 0.778 (0.704-0.802) and 13.6 (0.135) for VAI, 0.712 (0.700-0.729) and 12.2 (0.200) for BMI, 0.778 (0.704-0.802) and 17.0 (\< 0.0.048) for WHtR, and 0.778 (0.704-0.802) and 14.6 (0.103) for WHpR. The Harrell\'s *C*(95% CIs) and NamD\'Agostino *χ*^2^(P for lack of fit) for the CVD risk based on the Framingham general CVD algorithm were 0.841 (0.820-0.862) and 13.9 (0.126) among women. The corresponding figures were 0.841 (0.820-0.862) and 11.1 (0.266) for VAI, 0.835 (0.814-0.858) and 35.9 (\< 0.001) for BMI, 0.838 (0.816-0.859) and 42.0 (\< 0.0001) for WHtR, and 0.839 (0.8170.860) and 23.2 (0.005) for WHpR.

As shown in Table [4](#T4){ref-type="table"}, VAI failed to add to the predictive ability of the Framingham general CVD algorithm. Moreover, among women, when VAI was directly compared to the WHtR, WHpR, and BMI, NRI and IDI statistics were negative, indicating that WHpR, WHtR, and BMI predicted CVD better than did VAI. The only exception insinuated to the findings was that, among men, VAI outperformed BMI as denoted by all indices of added predictive abilities.

###### 

Added predictive ability conferred by VAI. male

                                         Women         Men                                                                
  ----------------------------- -------- ------------- ------------- --------------- ------------- ------------- -------- -------
                                         **95% CIs**   **P-value**   **Statistic**   **95% CIs**   **P-value**            
                                                                                                                          
  General CVD risk^b^                                                                                                     
   Absolute IDI (%)             -0.005   -0.009        -0.002        0.004           -0.003        -0.006        -0.001   0.006
   Relative IDI (%)             -0.039   -0.064        -0.014        0.002           -0.025        -0.042        -0.007   0.005
   Cut-point-based NRI ^c^(%)   -0.018   -0.053        0.017         0.310           -0.004        -0.028        0.021    0.764
   Cut-point-free NRI (%)       -0.221   -0.354        -0.089        0.001           -0.173        -0.258        -0.089   0.000
  WHtR                                                                                                                    
   Absolute IDI (%)             -0.044   -0.054        -0.035        0.000           -0.017        -0.022        -0.012   0.000
   Relative IDI (%)             -0.262   -0.298        -0.225        0.000           -0.115        -0.147        -0.084   0.000
   Cut-point-based NRI ^c^(%)   -0.077   -0.141        -0.013        0.019           -0.008        -0.042        0.025    0.632
   Cut-point-free NRI (%)       -0.052   -0.140        0.036         0.250           0.010         -0.070        0.091    0.800
  WHpR                                                                                                                    
   Absolute IDI (%)             -0.028   -0.037        -0.020        0.000           -0.012        -0.017        -0.008   0.000
   Relative IDI (%)             -0.185   -0.228        -0.142        0.000           -0.085        -0.113        -0.057   0.000
   Cut-point-based NRI ^c^(%)   -0.027   -0.084        0.030         0.345           0.003         -0.030        0.035    0.878
   Cut-point-free NRI (%)       -0.177   -0.294        -0.060        0.003           -0.122        -0.207        -0.037   0.005
  BMI                                                                                                                     
   Absolute IDI (%)             -0.038   -0.047        -0.029        0.000           0.055         0.042         0.068    0.000
   Relative IDI (%)             -0.233   -0.270        -0.197        0.000           0.727         0.481         0.973    0.000
   Cut-point-based NRI ^c^(%)   -0.067   -0.125        -0.010        0.022           0.346         0.286         0.406    0.000
   Cut-point-free NRI (%)       -0.031   -0.120        0.059         0.501           0.507         0.423         0.592    0.000

BMI, body mass index; CVD, cardiovascular disease; IDI, integrated discrimination improvement index; NRI, net reclassification improvement index; VAI, visceral adiposity index; WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio

a\. Negative signs indicate less predictive ability for VAI as compared to the general CVD algorithm, WHtR, WHpR, or BMI

b\. Calculated in accordance with D\'Agostino, R.B., Sr., et al., *General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study*. Circulation, 2008. **117**(6): p. 743-753

For cut-point based NRI, the cut-points were set at 0.05, 0.1, and 0.2 of estimated risk

Multivariate restricted cubic splines regression analysis demonstrated that VAI-CVD dose- response relations had no threshold and yielded straight lines when risk of disease was plotted on a logarithmic scale (Figure [3](#F3){ref-type="fig"}). The incident CVD risk corresponding to VAI = 2.3 was null; above this value VAI conferred hazard for incident CVD in a linear fashion. VAI values below 2.3 appeared to provide some protection against CVD.

![**Non-linear contribution of the visceral adiposity index to the risk of incident cardiovascular disease**.](1475-2840-11-20-3){#F3}

HRs for incident CVD of lifestyle modification intervention measures was 0.89 (95% CIs 0.70-1.12, P value = 0.324) among men and 1.11 (95% 0.85-1.45, P value = 0.435) among women. Intervention measures did not contribute to the risk of CVD; neither did the intervention measures modify the effects of VAI on the risk of incident CVD (P for interaction: men 0.304 and women 0.711).

VIFs were all \< 10 and therefore collinearity did not appear to be a problem.

Discussion
==========

In this prospective cohort of men and women, we found associations between higher VAI and risk of incident CVD as compared to simple, commonly available anthropometric measures. This community-based study demonstrated that a 1-SD increase in VAI carries 18-27% increase in age-adjusted risk of future CVD. After adjustment for traditional CVD risk factors however, it was only among women that VAI retained its predictability for incident CVD events. VAI failed to add to the predictive ability of the Framingham\'s \"general CVD algorithm,\" neither it did so to those of BMI, WHpR, or WHtR. The interesting finding of our study was that using VAI instead of simple anthropometric measures of adiposity may lead to loss of considerable information needed for predicting incident CVD. WHtR and WHpR explained greater part of variations in the CVD-free survival time than VAI did.

Establishing the shape of associations between risk factors and CVD is important to gauge the potential for prevention \[[@B22],[@B23]\]. We observed that dose-response association between VAI and CVD risk had no threshold. The incident CVD risk corresponding to the VAI = 2.3 was null. However, the slope of the dose-response association was steeper for VAI values smaller than 2.3 than those greater than 2.3. VAI values below 2.3 appeared to provide some protection against CVD. Above this value VAI conferred hazard for incident CVD in a linear fashion. As such, irrespective of the level of the VAI, a given increase in VAI levels above 2.3 would be accompanied by the same proportional increase in risk of incident CVD regardless of the initial risk. Meanwhile, a given decrease in VAI levels below 2.3 would be accompanied by the same proportional reduction in risk of incident CVD regardless of the initial risk. Our findings support previous reports showing the best cut-off point for VAI to be around 2.2 \[[@B24]\].

Adjusting for potential intermediates in the association between adiposity and CVD generally attenuates relative risks for the various indices \[[@B25],[@B26]\]. We observed that after adjustment for CVD risk factors, men\'s VAI levels were no longer associated with risk of incident CVD. Moreover, VAI did not improve the predictive ability of the Framingham general CVD risk prediction rule; WHtR and in particular WHpR were both superior to VAI in predicting risk of incident CVD, particularly among women. We also estimated the improvements across different categories of risk of the Framingham risk algorithm and observed negligible improvements. Only one percent of participants with moderate CVD risk were correctly reclassified (data are available upon the request). It has been shown that measures of adiposity are correlated with cardiovascular risk although no single adiposity measure can be identified as the best predictor \[[@B27]\]. In line with our findings, however, WHtR and WHpR have been shown to be superior to BMI \[[@B28]-[@B31]\]. Across quintiles of VAI, contribution of WHtR and WHpR to risk of incident CVD remained essentially the same (data available upon the request from authors); indicating that VAI did not modify effects of these risk factors on the risk of CVD. The finding that VAI was not better than WHpR or WHtR, at least in part, could possibly be explained by high correlation between WHpR and WHtR and components of VAI i.e. BMI, waist circumference, HDL-C, and TGs \[[@B32]\]. Anthropometric measures were previously demonstrated to keep pace with a combination of TGs and waist circumference, \"lipid accumulation product,\" in predicting incident CVD \[[@B5]\]. Technological developments including computer tomography scans and MRI, made it possible to precisely measure specific adipose tissue depots such as visceral adipose tissue mass \[[@B33]\]. We are aware of one prospective study in which visceral adiposity mass has directly been measured and compared to its anthropometric indices with respect to the CVD prediction \[[@B34]\]. Interestingly, clinical measurements of abdominal obesity were reported to be better predictors of CVD progression than tomography assessment in women \[[@B34]\]. These findings underscore the fact that there is so much room for investigations on adiposity measures that could improve CVD prediction above and beyond what have already been achieved by simple anthropometric measures.

The hypothesis that visceral adiposity would explain more variance in CVD risk factors than general adiposity was not supported in a relatively large sample of black and white adolescents \[[@B35]\].

\"Is the visceral adiposity worth the trouble or expenses involved in accurate measurements for prediction of future CVD?\" While current evidences point to the importance of using clinical measurements of abdominal obesity to identify individuals at increased risk for atherosclerosis \[[@B34]\], evidences are not firm enough to recommend precise measurement of the visceral adiposity mass for predicting incident CVD \[[@B27]\]. Moreover, Moebus et al. have demonstrated that the importance of different combinations of metabolic syndrome changes with age and between sexes putting emphasis on a tailored approach towards very young or very old subjects \[[@B36]\]. Sex- and age-specific VAI, thus, may confer stronger predictive capacity.

Strengths of the present study lie in its prospective nature, the use of a large population-based-cohort of both sexes, accurate and valid data on risk factors at baseline, continuous surveillance of mortality and CVD events based on standard criteria.

Some limitations to our study merit mentioning. First, in this study, no data was available about TGs lowering drugs. Second, the population studied was of Persian ancestry, our results, thus, cannot be readily extrapolated to other populations. The debate over how best to define visceral adiposity is complicated by observations suggesting that surrogates of adiposity may each perform better in predicting CVD risk in specific populations, depending on sex, age, and ethnicity \[[@B1]\].

Conclusion
==========

We demonstrated that the VAI was independently associated with an increased risk of incident CVD among women and that the magnitude of this risk due to VAI was not significantly higher than those due to BMI, WHpR, or WHtR. However, among men, after controlling common CVD risk factors, we observed that VAI was not associated with any significant increased risk of incident CVD. The increased risk observed among women, however, resisted all adjustment. Using VAI instead of simple anthropometric measures of adiposity may lead to loss of considerable information needed for predicting incident CVD.
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